Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 20, 2007, Pages 5510-5513

  Li, Jing ^a   Ma, Zhenkun ^a   Chapo, Katrina ^a   Yan, Dalai ^a   Lynch, A Simon ^a   Ding, Charles Z ^a  

^a Cumbre Pharmaceuticals Inc   (United States)

Author keywords

11 Deoxy 11 hydroxyiminorifamycins; Ansamycin; Anti staphylococcal; Antibacterial; Gram positive bacteria; MIC; Mycobacterium tuberculosis; Oxime; Rifalazil; Rifampin; Rifampin resistance; Rifamycin; RNA polymerase; S. aureus; Staphylococcus aureus

Indexed keywords

RIFALAZIL; RIFAMPICIN; RIFAMYCIN; RIFAMYCIN DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; WILD TYPE;

ANTI-BACTERIAL AGENTS; HYDROXYLATION; IMINES; MOLECULAR STRUCTURE; OXYGEN; RIFAMYCINS; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP;

MYCOBACTERIUM TUBERCULOSIS; POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 34548574628     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.08.048     Document Type: Article

References (17)

1. Flosss H.G., and Yu T.-W. Chem. Rev. 105 (2005) 621
2. Brufani M. J. Mol. Biol. 87 (1974) 409
3. American Thoracic Society Document Am. J. Respir. Crit. Care Med. 2003, 167, 603-662.
4. Zavasky D.-M., and Sande M.A. J. Am. Med. Assoc. 279 (1998) 1575
5. Zimmerli W., Widmer A.F., Blatter M., Frei R., and Ochsner P.E. J. Am. Med. Assoc. 279 (1998) 1537
6. Darouichi R.O. N. Engl. J. Med. 350 (2004) 1422
7. Heldman A.W. Am. J. Med. 101 (1996) 68
8. Wilson W.R., et al. J. Am. Med. Assoc 274 (1995) 1706
9. Karchmer A.W., Archer G.L., and Dismukes W.E. Rev. Infect. Dis. Suppl. 3 (1983) S543
10. Kim I., Combrink K.D., Ma Z., Chapo K., Yan D., Renick P., Morris T., Pulse M., Simecka J.W., and Ding C.Z. Bioor. Med. Chem. Lett. 17 (2007) 1181
11. Bartolucci C., Cellai L., Cerrini S., Lamba D., Segre A.L., Brizzi V., and Brufani M. Helvetica Chimica Acta 73 (1990) 185
12. See ActivBiotic company's website: (www.activbiotics.com/companyNews/index.html).
13. Rothstein D.M., Farquhar R.S., Sirokman K., Sondergaard K.L., Hazlett C., Doye A.A., Gwathmey J.K., Mullen S., van Duzer J., and Murphy C.K. Antimicrob. Agents Chemother. 50 (2006) 3658
14. Murphy C.K., Mullen S., Osburne M.S., van Duzer J., Siedlecki J., Yu X., Kerstein K., Cynamon M., and Rothstein D.M. Antimicrob. Agents Chemother. 50 (2006) 827
15. Rothstein D.M., Shalish C., Murphy C.K., Steinlicht A., and Campbell L.A. Expert Opin. Invest. Drugs 15 (2006) 603
16. Rothstein D.M., Hartman A.D., Cynamon M.H., and Eisenstein B.I. Expert Opin. Invest. Drugs 12 (2003) 255
17. Yamane T., Hashizume T., Yamashita K., Konishi E., Hosoe K., Hidaka T., Watanabe K., Kawaharada H., Yamamoto T., and Kuze F. Chem. Pharm. Bull. 41 (1993) 148